



ABSTRACT BOOK

SCIENTIFIC COMMITTEE

Ivana Munitić and Miranda Mladinić Pejatović (Department of Biotechnology, University of Rijeka, Croatia)

Emanuele Buratti (ICGEB Trieste, Italy)

Jasna Kriz and Jean-Pierre Julien (Laval University, Canada)

Ervina Bilić (Clinical Hospital Center Zagreb, Croatia)

Vladimira Vuletić (Clinical Hospital Center Rijeka, Croatia)

Srećko Gajović and Dinko Mitrečić (University of Zagreb School of Medicine, Croatia)

Pavle Andjus (University of Belgrade, Serbia)

Jasenka Mršić-Pelčić (Faculty of Medicine Rijeka, Croatia)

ORGANIZING COMMITTEE

Jelena Ban, Katarina Bulić, Marin Dominović, Josip Peradinović, Nikolina Prtenjača, Toni Franjlić, Zrinko Baričević, Ante Maslač, Sara Moržan and Marta Kolaric (Department of Biotechnology, University of Rijeka, Croatia)

Tomislav Pavlešić (University of Rijeka, Croatia)

Andrea Markovinović (King's College London, London, UK)



UNIRI



COZZI, MARTA

Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy

Co-authors: Barbara Tedesco^{1,2}, Riccardo Cristofani¹, Veronica Ferrari¹, Elena Casarotto¹, Marta Chierichetti¹, Francesco Mina¹, Margherita Piccolella¹, Mariarita Galbiati¹, Paola Rusmini¹, Valeria Crippa¹, Cinzia Gellera², Stefania Magri², Serena Santangelo^{3,4}, Antonia Ratti^{3,4}, Franco Taroni², Angelo Poletti¹

¹Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy

²Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

³Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy

⁴Department of Neurology and Stroke Unit – Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy

Investigating the molecular mechanisms involved in KIF5A-related neurodegeneration

Mutations targeting the neuron-specific kinesin KIF5A lead to neurodegenerative diseases (NDs), including amyotrophic lateral sclerosis (ALS). Distinct phenotypes develop according to which of the three KIF5A domains is affected by mutations, but the reasons behind such heterogeneity are not known yet. Our aim is to gain insight into the molecular mechanisms underlying KIF5A-related NDs by functionally characterizing four domain-specific KIF5A mutants (R17Q, R280C, R864*, N999Vfs*39). Overexpression in SH-SY5Y cells evidenced altered protein turnover for R17Q KIF5A and the ALS-related N999Vfs*39 mutant with respect to wild-type (WT) KIF5A, with the two mutants displaying shorter half-life upon cycloheximide chase. Higher accumulation was observed for R17Q and N999Vfs*39 KIF5A compared to WT KIF5A and the other KIF5A variants following proteasomal blockage, indicating that the ubiquitin-proteasome system might represent the main degradation route for the two mutants. R17Q and N999Vfs*39 KIF5A also displayed preferential partitioning in the detergent-insoluble protein fraction upon proteasome inhibition, which suggests they may form harmful inclusions when proteostasis is impaired. Altered intracellular distribution was evidenced for R864* and N999Vfs*39 KIF5A overexpressed in NSC-34 cells, with the two mutants mainly localizing at cell periphery instead of being diffused within the whole motoneuron like WT KIF5A. In particular, the ALS-related N999Vfs*39 mutant formed puncta inside cell processes, which hints at reduced protein solubility even in basal conditions, and partially sequestered WT KIF5A within them. The abnormal distribution displayed by R864* and N999Vfs*39 KIF5A was paralleled by limited colocalization between the two mutants and mitochondria, whose axonal transport is largely reliant on WT KIF5A in motoneurons. Taken together, our preliminary observations indicate that both unique and shared mechanisms might underlie the pathogenesis of KIF5A-related NDs.